As regards the latter, our findings suggest that the efficacy of Bor on MM could be improved by the combination with agents such as UPR modulators and AKT-targeting agents and that, on the other hand, Bor could improve the therapeutic outcomes of immunotherapy and immune checkpoint inhibitors-based treatments. This evidence concerns the gene AKT1 and Miyoshi myopathy.